RestructuringJun 12, 2026, 04:12 PM
Soligenix Terminates HyBryte™ Program; Faces Nasdaq Delisting Notice
AI Summary
Soligenix has terminated its HyBryte™ development program after the Phase 3 FLASH2 clinical trial was halted for futility, expecting approximately $70,000 in wind-down charges. Concurrently, the company received a Nasdaq notice for non-compliance with the $1.00 minimum bid price rule, with 180 days to regain compliance by December 7, 2026. Following the program termination, Dr. Richard C. Straube ceased serving as Consulting Chief Medical Officer, with his responsibilities transitioning to Dr. Christopher Pullion. The company is now evaluating strategic options, including M&A and advancing other pipeline programs like dusquetide.
Key Highlights
- Soligenix terminated its HyBryte™ development program after the Phase 3 FLASH2 clinical trial was halted for futility.
- The company expects to incur approximately $70,000 in charges for the HyBryte™ program wind-down.
- Received a Nasdaq notice for non-compliance with the $1.00 minimum bid price requirement (Rule 5550(a)(2)).
- Has 180 calendar days, until December 7, 2026, to regain Nasdaq compliance.
- Dr. Richard C. Straube ceased serving as Consulting Chief Medical Officer on June 11, 2026.
- Dr. Christopher Pullion, Medical Director, will assume Dr. Straube's responsibilities.
- The company is evaluating strategic options and other pipeline programs, including dusquetide.
Price Impact
More from SNGX